In the same way that promise has arisen from the use of myosin inhibitors, there is excitement about the potential use of agents such as danicamtiv and omecamtiv mecarbil that increase actin-myosin cross-bridging in sarcomeric DCM (Voors et al., 2020; Teerlink et al., 2021). Here, MYH14 is linked to familial dilated cardiomyopathy.